Neutrino Biotechnologies (India) Private Limited
Fish hatchery business since 2010, based in Tamil Nadu.
2010 | Chennai, Tamil Nadu (India) | Active
Neutrino Biotechnologies (India) Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 14 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 5.24%
- Profit Growth 21.73%
- Ebitda 51.87%
- Net Worth 14.87%
- Total Assets 5.80%
About Neutrino Biotechnologies (India)
Neutrino Biotechnologies (India) Private Limited (NBIPL) is a Private Limited Indian Non-Government Company incorporated in India on 19 November 2010 and has a history of 14 years and three months. Its registered office is in Chennai, Tamil Nadu, India.
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Karuppiah Anand and Gangatharan Ramesh serve as directors at the Company.
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U05001TN2010PTC078136
- Company No.
078136
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Nov 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Agriculture
Who are the key members and board of directors at Neutrino Biotechnologies (India)?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gangatharan Ramesh  | Director | 19-Nov-2010 | Current |
| Karuppiah Anand | Director | 19-Nov-2010 | Current |
Financial Performance of Neutrino Biotechnologies (India).
Neutrino Biotechnologies (India) Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 5.24% increase. The company also saw a substantial improvement in profitability, with a 21.73% increase in profit. The company's net worth Soared by an impressive increase of 14.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Neutrino Biotechnologies (India)?
In 2023, Neutrino Biotechnologies (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Neutrino Biotechnologies (India)?
Unlock and access historical data on people associated with Neutrino Biotechnologies (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Neutrino Biotechnologies (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Neutrino Biotechnologies (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.